Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) saw an uptick in trading volume on Wednesday after Needham & Company LLC raised their price target on the stock from $30.00 to $33.00. Needham & Company LLC currently has a buy rating on the stock. 1,343,090 shares traded hands during mid-day trading, an increase of 85% from the previous session’s volume of 726,171 shares.The stock last traded at $15.66 and had previously closed at $16.64.
Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Piper Sandler reiterated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.67.
Check Out Our Latest Stock Report on DAWN
Insiders Place Their Bets
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC acquired a new stake in Day One Biopharmaceuticals in the fourth quarter valued at $29,000. China Universal Asset Management Co. Ltd. lifted its stake in Day One Biopharmaceuticals by 130.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after acquiring an additional 1,262 shares during the last quarter. Quintet Private Bank Europe S.A. lifted its stake in Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares during the last quarter. Amalgamated Bank lifted its stake in Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after acquiring an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after acquiring an additional 2,554 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.
Day One Biopharmaceuticals Stock Down 5.8 %
The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -6.58 and a beta of -1.48. The business’s 50 day simple moving average is $15.27 and its 200 day simple moving average is $13.78.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last posted its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Articles
- Five stocks we like better than Day One Biopharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
- Following Congress Stock Trades
- GE Aerospace is Ready for Liftoff After Strong Earnings
- Market Cap Calculator: How to Calculate Market Cap
- The Bottom is in For Tesla: Read This Before Buying the Bounce
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.